Cogent Biosciences, Inc. (COGT)
Nasdaq: COGT · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2014
Who owns Cogent Biosciences, Inc.
As filed with the SECHolders of 5% or more
4
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 12, 2025 says.
Directors and officers
13
report now, of 23 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 12, 2025 · COMMON STOCK
Fairmount Funds Management LLC
SCHEDULE 13D/A · filed Mar 31, 2026 · Common Stock, $0.001 par value · 9.9% in Jan 22, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 6.5% in Jan 21, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
TCG Crossover GP I, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
Kynam Capital Management, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 · reported falling below 5%, from 5.54% in Nov 14, 2025
Venrock Healthcare Capital Partners II, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.8% in Apr 11, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 8.7% in Feb 14, 2025
Deerfield Mgmt, L.P.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · reported falling below 5%, from 5.29% in May 14, 2026
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 9.1% in Aug 14, 2025
Commodore Capital LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 7.2% in Nov 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 7.5% in Jan 30, 2026
What COGT reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 17, 2026.
Insider tradesForm 4
8sales
0purchases
2sales on a scheduled plan
6people selling
$384Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 5, 2025 to Oct 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | director | 2 | $370M | 0 | 0 | $0 |
| Robinson John Edward | Chief Scientific Officer | 1 | $3.5M | 0 | 0 | $0 |
| Sachs Jessica | Chief Medical Officer | 1 | $3.2M | 0 | 0 | $0 |
| Green John L. | Chief Financial Officer | 1 | $3.0M | 0 | 0 | $0 |
| Kearns Evan | Chief Legal Officer | 1 | $2.5M | 0 | 0 | $0 |
| Morris Arlene | director | 2 | $1.7M | 2 | 0 | $0 |